Labopharm to submit once-daily trazodone
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Labopharm intends to file its once-daily version of the antidepressant trazodone using the 505(b)(2) pathway by the end of 2008, the firm said Feb. 8 after announcing positive Phase III results. Labopharm is touting the formulation's ability to "significantly improve the overall quality of sleep [with] less awakening at night." Labopharm believes that the once-daily option that reduces agitation and improves sleep quality will reduce the need for add-on therapies and be well-positioned in the antidepressant marketplace. Once-daily trazodone met the primary endpoint (HAMD-17) in the 8-week placebo-controlled study of 412 patients with major depression. The dropout rate was 21 percent for placebo and 30.2 percent for trazodone, with 4 percent of those patients discontinuing due to somnolence or sedation...
You may also be interested in...
Labopharm Tramadol-Acetaminophen Combo Could Offer Twice-Daily Dosing
Canadian firm initiates Phase III trial evaluating the combination for treatment of acute lower back pain
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.